-
公开(公告)号：US10752676B2
公开(公告)日：2020-08-25
申请号：US14344637
申请日：2012-09-10
申请人： David Paul Humphreys , Daniel John Lightwood , Kerry Louise Tyson , David Edward Ormonde Knight , Karine Jeannine Madeleine Hervé , Joanne Elizabeth Compson , Matthew Jon Timothy Page , Andrew Charles Payne , Nicola Louise Fisher , Brendon Mackenzie , Matthew Cox
发明人： David Paul Humphreys , Daniel John Lightwood , Kerry Louise Tyson , David Edward Ormonde Knight , Karine Jeannine Madeleine Hervé , Joanne Elizabeth Compson , Matthew Jon Timothy Page , Andrew Charles Payne , Nicola Louise Fisher , Brendon Mackenzie , Matthew Cox
IPC分类号： C07K16/12 , A61K39/40 , A61K45/06 , A61K39/00 , G01N33/569 , G01N33/573 , G01N33/68
摘要： This present invention describes the derivation and selection of antibodies capable of neutralising the major exotoxins; TcdA and TcdB of Clostridium difficile. The invention also describes novel neutralisation and antigen binding properties of individual Mabs and mixtures thereof.
-
2.发明申请NEUTRALISING ANTIBODIES TO THE MAJOR EXOTOXINS TCDA AND TCDB OF CLOSTRIDIUM DIFFICILE 审中-公开中枢性抗体对主要外源性TCDA和TCDB的CLOSTRIDIUM DIFFICILE公开(公告)号：US20140348844A1
公开(公告)日：2014-11-27
申请号：US14344637
申请日：2012-09-10
申请人： David Paul Humphreys , Daniel John Lightwood , Kerry Louise Tyson , David Edward Ormonde Knight , Karine Jeannine Madeleine Hervé , Joanne Elizabeth Compson , Matthew Jon Timothy Page , Andrew Charles Payne , Nicola Louise Fisher , Brendon Mackenze , Matthew Cox
发明人： David Paul Humphreys , Daniel John Lightwood , Kerry Louise Tyson , David Edward Ormonde Knight , Karine Jeannine Madeleine Hervé , Joanne Elizabeth Compson , Matthew Jon Timothy Page , Andrew Charles Payne , Nicola Louise Fisher , Brendon Mackenze , Matthew Cox
IPC分类号： C07K16/12 , G01N33/573 , G01N33/68 , G01N33/569 , A61K39/40 , A61K45/06
摘要： This present invention describes the derivation and selection of antibodies capable of neutralising the major exotoxins; TcdA and TcdB of Clostridium difficile. The invention also describes novel neutralisation and antigen binding properties of individual Mabs and mixtures thereof.
摘要翻译： 本发明描述了能够中和主要外毒素的抗体的衍生和选择; 艰难梭菌的TcdA和TcdB。 本发明还描述了单个Mab及其混合物的新型中和和抗原结合性质。
-
公开(公告)号：US20100260773A1
公开(公告)日：2010-10-14
申请号：US12720804
申请日：2010-03-10
申请人： Neil Gozzard , Alastair David Griffiths Lawson , Daniel John Lightwood , Roger Thomas Palframan , Bryan John Smith , Kerry Louise Tyson
发明人： Neil Gozzard , Alastair David Griffiths Lawson , Daniel John Lightwood , Roger Thomas Palframan , Bryan John Smith , Kerry Louise Tyson
IPC分类号： A61K39/395 , C07K16/00 , C07H21/04 , C12N15/63 , A61P11/06 , A61P35/00 , A61P37/00 , A61P31/12 , A61P9/00 , C12P21/00 , C12N1/21 , C12N5/07
CPC分类号： C07K16/244 , A61K9/0078 , A61K39/395 , A61K39/3955 , A61K2039/505 , A61K2039/544 , C07K2317/24 , C07K2317/33 , C07K2317/51 , C07K2317/515 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要： The invention relates to antibody molecules having specificity for antigenic determinants of human IL-13, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
摘要翻译： 本发明涉及对人IL-13的抗原决定簇具有特异性的抗体分子，抗体分子的治疗用途以及产生所述抗体分子的方法。
-
公开(公告)号：US08691233B2
公开(公告)日：2014-04-08
申请号：US12720804
申请日：2010-03-10
申请人： Neil Gozzard , Alastair David Griffiths Lawson , Daniel John Lightwood , Roger Thomas Palframan , Bryan John Smith , Kerry Louise Tyson
发明人： Neil Gozzard , Alastair David Griffiths Lawson , Daniel John Lightwood , Roger Thomas Palframan , Bryan John Smith , Kerry Louise Tyson
CPC分类号： C07K16/244 , A61K9/0078 , A61K39/395 , A61K39/3955 , A61K2039/505 , A61K2039/544 , C07K2317/24 , C07K2317/33 , C07K2317/51 , C07K2317/515 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要： The invention relates to antibody molecules having specificity for antigenic determinants of human IL-13, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
摘要翻译： 本发明涉及对人IL-13的抗原决定簇具有特异性的抗体分子，抗体分子的治疗用途以及产生所述抗体分子的方法。
-
公开(公告)号：US20110229461A1
公开(公告)日：2011-09-22
申请号：US13045718
申请日：2011-03-11
申请人： Kerry Louise Tyson
发明人： Kerry Louise Tyson
IPC分类号： A61K39/395 , C07K16/28 , C07H21/04 , A61P37/00 , A61P19/02 , A61P25/00 , A61P1/00 , A61P3/10 , A61P35/00 , A61P31/00 , C12N15/63 , C12P21/02 , C12N1/00 , C12N5/10
CPC分类号： C07K14/70503 , C07K16/2818 , C07K2317/24 , C07K2317/33 , C07K2317/51 , C07K2317/515 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/75 , C07K2317/92
摘要： A humanised agonistic antibody which binds human PD-1 comprising a heavy chain and a light chain wherein the variable domain of the heavy chain comprises the sequence given in SEQ ID NO:1 for CDR-H1, the sequence given in SEQ ID NO:2 for CDR-H2 and the sequence given in SEQ ID NO:3 for CDR-H3 and the variable domain of the light chain comprises the sequence given in SEQ ID NO:4 for CDR-L1, the sequence given in SEQ ID NO:5 for CDR-L2 and the sequence given in SEQ ID NO:7 for CDR-L3. The invention also extends to therapeutic uses of the antibody molecules, compositions and methods for producing said antibody molecules.
摘要翻译： 结合包含重链和轻链的人PD-1的人源化激动抗体，其中重链的可变结构域包含SEQ ID NO：1中针对CDR-H1给出的序列，SEQ ID NO：2中给出的序列 对于CDR-H2和CDR-H3的SEQ ID NO：3中给出的序列，轻链的可变结构域包含SEQ ID NO：4中针对CDR-L1给出的序列，SEQ ID NO：5中给出的序列 对于CDR-L2和针对CDR-L3的SEQ ID NO：7中给出的序列。 本发明还延伸到抗体分子的治疗用途，用于产生所述抗体分子的组合物和方法。
-
公开(公告)号：US20090326203A1
公开(公告)日：2009-12-31
申请号：US12307051
申请日：2007-06-26
CPC分类号： C07K16/464 , C07K16/465 , C07K2317/24 , C07K2317/92
摘要： The present invention relates to improved methods for the selection of appropriate human acceptor framework regions for non-human (donor) antibodies and methods for obtaining humanized antibodies of high affinity using such acceptor frameworks.
摘要翻译： 本发明涉及用于选择非人（供体）抗体的合适的人受体框架区的改进方法和使用这种受体框架获得高亲和力的人源化抗体的方法。
-
公开(公告)号：US07273744B2
公开(公告)日：2007-09-25
申请号：US10177245
申请日：2002-06-21
申请人： Edward Alexander McKenzie , Alasdair Craig Stamps , Jonathan Alexander Terrett , Kerry Louise Tyson
发明人： Edward Alexander McKenzie , Alasdair Craig Stamps , Jonathan Alexander Terrett , Kerry Louise Tyson
CPC分类号： C12Y302/01166 , C12N9/2402
摘要： The present invention provides a homologue to heparanase which is present in three splice variants.
摘要翻译： 本发明提供了存在于三个剪接变体中的乙酰肝素酶的同源物。
-
公开(公告)号：US09249232B2
公开(公告)日：2016-02-02
申请号：US12307051
申请日：2007-06-26
CPC分类号： C07K16/464 , C07K16/465 , C07K2317/24 , C07K2317/92
摘要： The present invention relates to improved methods for the selection of appropriate human acceptor framework regions for non-human (donor) antibodies and methods for obtaining humanized antibodies of high affinity using such acceptor frameworks.
摘要翻译： 本发明涉及用于选择非人（供体）抗体的合适的人受体框架区的改进方法和使用这种受体框架获得高亲和力的人源化抗体的方法。
-
公开(公告)号：US20090246201A1
公开(公告)日：2009-10-01
申请号：US11893095
申请日：2007-08-14
申请人： Edward Alexander McKenzie , Alasdair Craig Stamps , Jonathan Alexander Terrett , Kerry Louise Tyson
发明人： Edward Alexander McKenzie , Alasdair Craig Stamps , Jonathan Alexander Terrett , Kerry Louise Tyson
IPC分类号： A61K39/395 , C12N9/10 , C07K16/18 , C12N15/11 , C12N15/00 , C12N5/06 , C12P21/02 , A61K38/45 , C12Q1/48
CPC分类号： C12Y302/01166 , C12N9/2402
摘要： The present invention provides a homologue to heparanase which is present in three splice variants.
摘要翻译： 本发明提供了存在于三个剪接变体中的乙酰肝素酶的同源物。
-
公开(公告)号：US09102728B2
公开(公告)日：2015-08-11
申请号：US13045718
申请日：2011-03-11
申请人： Kerry Louise Tyson
发明人： Kerry Louise Tyson
IPC分类号： C07K16/28
CPC分类号： C07K14/70503 , C07K16/2818 , C07K2317/24 , C07K2317/33 , C07K2317/51 , C07K2317/515 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/75 , C07K2317/92
摘要： A humanised agonistic antibody which binds human PD-1 comprising a heavy chain and a light chain wherein the variable domain of the heavy chain comprises the sequence given in SEQ ID NO:1 for CDR-H1, the sequence given in SEQ ID NO:2 for CDR-H2 and the sequence given in SEQ ID NO:3 for CDR-H3 and the variable domain of the light chain comprises the sequence given in SEQ ID NO:4 for CDR-L1, the sequence given in SEQ ID NO:5 for CDR-L2 and the sequence given in SEQ ID NO:7 for CDR-L3. The invention also extends to therapeutic uses of the antibody molecules, compositions and methods for producing said antibody molecules.
摘要翻译： 结合包含重链和轻链的人PD-1的人源化激动抗体，其中重链的可变结构域包含SEQ ID NO：1中针对CDR-H1给出的序列，SEQ ID NO：2中给出的序列 对于CDR-H2和CDR-H3的SEQ ID NO：3中给出的序列，轻链的可变结构域包含SEQ ID NO：4中针对CDR-L1给出的序列，SEQ ID NO：5中给出的序列 对于CDR-L2和针对CDR-L3的SEQ ID NO：7中给出的序列。 本发明还延伸到抗体分子的治疗用途，用于产生所述抗体分子的组合物和方法。
-
-
-
-
-
-
-
-
-
搜索结果
17 条记录 (耗时 0.052 秒)